Suppr超能文献

评估疫苗上市后安全性面临的挑战:来自疾病预防控制中心的观察。

Challenges in evaluating post-licensure vaccine safety: observations from the Centers for Disease Control and Prevention.

机构信息

Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

出版信息

Expert Rev Vaccines. 2019 Oct;18(10):1091-1101. doi: 10.1080/14760584.2019.1676154. Epub 2019 Oct 19.

Abstract

: Vaccination is one of the most successful and cost-effective public health interventions. Although vaccines undergo extensive safety and efficacy evaluations prior to licensure, vaccine safety assessment post-licensure is essential for detecting rare and longer-term adverse events (AEs) and maintaining public confidence in vaccines and recommended immunization programs. Despite the proven effect of vaccines to save lives and prevent disease and overwhelming evidence of vaccines' safety and societal benefit, like any drug, no vaccine can be considered as completely safe and completely effective. New vaccines continue to be introduced and require rapid safety assessment post-licensure through pharmacovigilance reports as well as epidemiologic studies to investigate any potential safety signals.: We discuss selected challenges for conducting pharmacovigilance and epidemiologic studies of AEs after vaccination in the United States using the post-licensure safety surveillance infrastructure of the Centers for Disease Control and Prevention (CDC).: The availability of specific post-licensure surveillance systems to monitor and study AEs after vaccination, such as the Vaccine Adverse Event Reporting System, the Vaccine Safety Datalink, and the Clinical Immunization Safety Assessment Project, each with its unique set of strengths and limitations, provide a harmonized and supportive approach to meet several of these barriers.

摘要

疫苗接种是最成功和最具成本效益的公共卫生干预措施之一。尽管疫苗在获得许可前要经过广泛的安全性和有效性评估,但在获得许可后对疫苗安全性进行评估对于发现罕见和长期的不良事件(AE)以及维护公众对疫苗和推荐免疫计划的信心至关重要。尽管疫苗在拯救生命和预防疾病方面的效果已得到证实,并且疫苗的安全性和社会效益的证据压倒性,但与任何药物一样,没有一种疫苗可以被认为是完全安全和完全有效的。新疫苗不断推出,需要通过药物警戒报告以及流行病学研究,在获得许可后快速进行安全性评估,以调查任何潜在的安全信号。

我们讨论了在美国使用疾病预防控制中心(CDC)的上市后安全性监测基础设施进行疫苗接种后不良事件(AE)的药物警戒和流行病学研究的一些选定挑战。

有专门的上市后监测系统可用于监测和研究疫苗接种后的 AE,例如疫苗不良事件报告系统、疫苗安全数据链接和临床免疫安全评估项目,每个系统都有其独特的优势和局限性,为应对其中的一些障碍提供了一种协调和支持的方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验